Project Grant R21HL181645
- The University of Rochester was awarded a $573,261 Project Grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to investigate the role of platelets in regulating monocyte immune responses during vascular inflammation. The 4-year research project, beginning August 1, 2025, aims to understand how resting platelets interact with monocytes to epigenetically "train" their innate immune responses, and how this process is altered by platelet...
- This Project Grant award for $814,387 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research to investigate the role of a novel subpopulation of innate lymphoid cells (ILC3s) in lung infections and vascular regeneration. The award recipient, The Trustees of Columbia University, will utilize mouse models, single-cell analysis, and in vitro assays to: Define the tissue niche and response dynamics of lung vascular ILC3s (VILC3s),...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the mechanosensitive mechanisms underlying angiogenesis and lung regeneration. The $618,838 award to the Medical College of Wisconsin aims to investigate how mechanical stretching forces control angiogenesis during compensatory lung growth after pneumonectomy. The research will focus on the role of the focal adhesion protein paxillin in regulating...
- This $1,831,848 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate how early-life disruptions to gut microbiota colonization can remodel the development of lung immune and epithelial cells, contributing to chronic respiratory diseases. The research aims to identify the critical window and key microbial taxa required for establishing long-term lung homeostasis. Preliminary data indicates that...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $730,070 to the University of Arizona to develop and test a novel class of hybrid polyplex nanoparticles (P22-F1 PBAE/PEI/PEG) that can specifically target and deliver DNA plasmids to lung capillary endothelial cells. The goal is to stimulate lung regeneration and decrease pulmonary hypertension in mouse and rat models of bronchopulmonary dysplasia, a severe...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to support research on modulating the resolution of angiogenesis and normalizing the vasculature for therapeutic benefit in cardiovascular diseases. The $549,665 award, effective January 15, 2025 through November 30, 2028, will fund research conducted by the University of Maryland, Baltimore to investigate mechanisms that regulate the resolution of angiogenesis,...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $759,983.00 to the University of North Carolina at Chapel Hill to conduct research on the role of neutrophils in lung infections and acute lung injury. The study aims to examine changes in neutrophil transcriptomes and function during Streptococcus pneumoniae pneumonia, with the goal of improving understanding of the lung's immune response and potential...
- This $229,608 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research investigating the role of pleural mesothelial cells in lung injury, repair, and regeneration. The award to Mayo Clinic aims to conduct lineage-tracing experiments in mouse models of lung injury and regeneration, and subsequent genomic analysis of the collected pleural mesothelial cells. This research seeks to improve the understanding of repair...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $775,720 project grant to Yale University under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to conduct research on the role of endothelial protocadherins in vascular development and disease. The project aims to: 1) determine the effects of knocking out or inhibiting the protocadherin gamma (PCDHG) cluster in endothelial cells in mouse models of vascular inflammation, 2) elucidate the mechanism by which...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $245,626 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, with a project period from February 1, 2025 to January 31, 2027, will fund research to validate lipidomic signatures associated with right ventricular and pulmonary vascular dysfunction in pulmonary arterial hypertension (PAH). The project aims to replicate the researchers' preliminary findings on...
The University of Rochester was awarded a $226,101 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on pulmonary angioblasts and their role in vascular development. The project aims to leverage existing single-cell RNA sequencing data to uncover novel insights into the cellular characteristics and regulatory mechanisms governing pulmonary angioblasts, which are critical for vascular regeneration and the treatment of vascular diseases. The research will focus on exploring the differentiation trajectory of pulmonary angioblasts and their derived cell types, as well as identifying the molecular markers and signaling pathways that drive their function. This work is aligned with the NIH's strategic priority of addressing critical gaps in knowledge through the reanalysis of existing data. The grant period runs from September 1, 2025, to August 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $226.1k | 8/22/25 |